Impact of Dupilumab on the Ability to Enjoy Life in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Alexa B. Kimball
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Min Yang
Analysis Group, Boston, Massachusetts, USA

Bruno Martins
Analysis Group, Boston, Massachusetts, USA

Ashley Holub
Analysis Group, Boston, Massachusetts, USA

Jingdong Chao
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA

Gaëlle Bégo-Le-Bagousse
Sanofi, Gentilly, France

Kerry Noonan
Sanofi, Cambridge, Massachusetts, USA

Zhixiao Wang
Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA

Keywords

atopic dermatiits, Dupilumab

References

1. Silverberg JI, et al. Ann Allergy Asthma Immunol.2018; 121:340–7.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/zsezf336

Article Details

How to Cite
1.
Impact of Dupilumab on the Ability to Enjoy Life in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin. 2025;9(6):s596. doi:10.25251/zsezf336
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Poster Presentations from FC25 Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>